Stress Testing

Ischemia Detection

As much as 40% of catheterizations performed are false-positive and 15% are false-negative.² To help reduce the number of unnecessary and suboptimal procedures made on false-positive and false-negative CAD patients, MyoStrain performs a rapid and quantitative assessment of heart function. 

In a 15-minute stress test, MyoStress™ helps physicians identify ischemic areas of the heart to rule-out healthy patients while ruling-in at-risk patients to determine a treatment plan best suited to the patient’s condition.

Chest Pain Triage

In the ER today, many of the common cardiac diagnostic tools used provide little explanation for chest pain, and physicians must run several cardiac tests while working under extensive time requirements in order to find the cause of the patient’s discomfort. These challenges put strain on the ER system, potentially leading to capacity constraints, unnecessary procedures and suboptimal care.

MyoStrain’s rapid, accurate and non-invasive hyperventilation stress test MyoStress™ is designed to help improve detection, enhance workflow efficiency and optimize care in the ER. Clinicians may potentially use MyoStress™ to quantitatively detect ischemia in high-risk chest pain patients while identifying heart dysfunction in lower to at-risk patients and directing them towards the most appropriate care decision. Through this approach, MyoStrain and MyoStress may help to improve outcomes in the ER, enabling clinicians to effectively triage their patients based on individual cardiac risk and reduce the number of unnecessary procedures performed.

Chest Pain Triage

In the ER today, many of the common cardiac diagnostic tools used provide little explanation for chest pain, and physicians must run several cardiac tests while working under extensive time requirements in order to find the cause of the patient’s discomfort. These challenges put strain on the ER system, potentially leading to capacity constraints, unnecessary procedures and suboptimal care.

MyoStrain’s rapid, accurate and non-invasive hyperventilation stress test MyoStress™ is designed to help improve detection, enhance workflow efficiency and optimize care in the ER. Clinicians may potentially use MyoStress™ to quantitatively detect ischemia in high-risk chest pain patients while identifying heart dysfunction in lower to at-risk patients and directing them towards the most appropriate care decision. Through this approach, MyoStrain and MyoStress may help to improve outcomes in the ER, enabling clinicians to effectively triage their patients based on individual cardiac risk and reduce the number of unnecessary procedures performed.

Chest Pain Triage

In the ER today, many of the common cardiac diagnostic tools used provide little explanation for chest pain, and physicians must run several cardiac tests while working under extensive time requirements in order to find the cause of the patient’s discomfort. These challenges put strain on the ER system, potentially leading to capacity constraints, unnecessary procedures and suboptimal care.

MyoStrain’s rapid, accurate and non-invasive hyperventilation stress test MyoStress™ is designed to help improve detection, enhance workflow efficiency and optimize care in the ER. Clinicians may potentially use MyoStress™ to quantitatively detect ischemia in high-risk chest pain patients while identifying heart dysfunction in lower to at-risk patients and directing them towards the most appropriate care decision. Through this approach, MyoStrain and MyoStress may help to improve outcomes in the ER, enabling clinicians to effectively triage their patients based on individual cardiac risk and reduce the number of unnecessary procedures performed.

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019